Regeneron Pharmaceuticals Inc. (REGN)’s Financial Results Comparing With Imprimis Pharmaceuticals Inc. (NASDAQ:IMMY)

As Biotechnology businesses, Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) and Imprimis Pharmaceuticals Inc. (NASDAQ:IMMY), are affected by compare. This especially applies to their dividends, institutional ownership, analyst recommendations, profitability, risk, earnings and valuation.

Valuation and Earnings

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Regeneron Pharmaceuticals Inc. 6.37B 6.91 1.80B 18.46 20.46
Imprimis Pharmaceuticals Inc. N/A 0.00 N/A -0.31 0.00

Table 1 showcases the gross revenue, earnings per share (EPS) and valuation of Regeneron Pharmaceuticals Inc. and Imprimis Pharmaceuticals Inc.

Profitability

Table 2 has Regeneron Pharmaceuticals Inc. and Imprimis Pharmaceuticals Inc.’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Regeneron Pharmaceuticals Inc. 28.26% 25.9% 18.5%
Imprimis Pharmaceuticals Inc. 0.00% -230.7% -25.2%

Risk and Volatility

Regeneron Pharmaceuticals Inc. has a 1.34 beta, while its volatility is 34.00%, thus making it more volatile than Standard & Poor’s 500. Competitively, Imprimis Pharmaceuticals Inc. is 187.00% less volatile than Standard & Poor’s 500, because of the -0.87 beta.

Liquidity

The Current Ratio and Quick Ratio of Regeneron Pharmaceuticals Inc. are 4 and 3.6 respectively. Its competitor Imprimis Pharmaceuticals Inc.’s Current Ratio is 1.1 and its Quick Ratio is 0.9. Regeneron Pharmaceuticals Inc. can pay off short and long-term obligations better than Imprimis Pharmaceuticals Inc.

Analyst Recommendations

The next table highlights the given recommendations and ratings for Regeneron Pharmaceuticals Inc. and Imprimis Pharmaceuticals Inc.

Sell Ratings Hold Ratings Buy Ratings Rating Score
Regeneron Pharmaceuticals Inc. 0 3 2 2.40
Imprimis Pharmaceuticals Inc. 0 0 1 3.00

The upside potential is 1.42% for Regeneron Pharmaceuticals Inc. with average price target of $412.33. On the other hand, Imprimis Pharmaceuticals Inc.’s potential upside is 75.75% and its average price target is $10. The data provided earlier shows that Imprimis Pharmaceuticals Inc. appears more favorable than Regeneron Pharmaceuticals Inc., based on analyst opinion.

Institutional & Insider Ownership

Regeneron Pharmaceuticals Inc. and Imprimis Pharmaceuticals Inc. has shares owned by institutional investors as follows: 73.7% and 23.3%. Insiders owned roughly 0.4% of Regeneron Pharmaceuticals Inc.’s shares. Comparatively, insiders own roughly 3.9% of Imprimis Pharmaceuticals Inc.’s shares.

Performance

In this table we provide the Week, Month, Quarter, Half Year, Year and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Regeneron Pharmaceuticals Inc. 3.27% 3.66% -4.42% 21.04% 1.07% 0.43%
Imprimis Pharmaceuticals Inc. 14.8% 23.69% 79.8% 118.95% 213.87% 219.41%

For the past year Regeneron Pharmaceuticals Inc. has weaker performance than Imprimis Pharmaceuticals Inc.

Summary

Regeneron Pharmaceuticals Inc. beats on 9 of the 12 factors Imprimis Pharmaceuticals Inc.

Regeneron Pharmaceuticals, Inc., a biopharmaceutical company, discovers, invents, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions worldwide. Its products include EYLEA injection for the treatment of neovascular age-related macular degeneration, diabetic macular edema, and macular edema following retinal vein occlusion; Praluent injection, an adjunct to diet and tolerated statin therapy for the treatment of adults with heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease; and ARCALYST injection for the treatment of cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome in adults and childrenÂ’s. It also markets Kevzara injection for the treatment of rheumatoid arthritis in adults; and ZALTRAP, an injection for intravenous infusion, which is used in combination with 5-fluorouracil, leucovorin, and irinotecan for the treatment of metastatic colorectal cancer. The company also develops EYLEA, trap-based clinical product that is in Phase III study for the treatment of neovascular glaucoma. Regeneron Pharmaceuticals, Inc. has collaboration agreement with Sanofi for the development of antibody-based clinical products comprising Praluent, Sarilumab, Dupixent, REGN2810, REGN3500, and REGN3767; Bayer HealthCare LLC for the development of Nesvacumab/aflibercept, which is used in ophthalmology; and with Teva and Mitsubishi Tanabe Pharma Corporation for developing Fasinumab, an antibody to nerve growth factor. It also has collaboration agreements with Intellia Therapeutics, Inc. to advance CRISPR/Cas gene-editing technology for in vivo therapeutic development; and the U.S. Department of Health and Human Services to develop treatments combating infectious diseases. The company was founded in 1988 and is headquartered in Tarrytown, New York.

Imprimis Pharmaceuticals, Inc. engages in the development, production, and sale of medications to physicians and patients in the United States. Its ophthalmology program consists of Dropless Therapy injectable and LessDrops topical formulations. The company also offers a conscious sedation medication, the IV Free MKO Melt, an alternative to intravenous sedation. It focuses on providing ophthalmology programs and medications for glaucoma, wet age-related macular degeneration, diabetic macular edema, and chronic dry eye disease. The companyÂ’s medicine business includes medications used in several therapeutic areas, including oncology, autoimmunity, chronic infectious diseases, and endocrine and metabolic diseases; and urology business comprises a series of injectable erectile dysfunction formulations for patients that are refractory to or are otherwise unable to take phosphodiesterase type 5 inhibitors, such as sildenafil, tadalafil, and vardenafil. In addition, it develops PPS-DR (pentosan polysulfate sodium delayed-release) formulations as alternatives to Elmiron for patients diagnosed with interstitial cystitis; and develops and sells therapeutic alternatives to Daraprim, Thiola, and Calcium Disodium Versenate. The company was formerly known as Transdel Pharmaceuticals, Inc. and changed its name to Imprimis Pharmaceuticals, Inc. in February 2012. Imprimis Pharmaceuticals, Inc. was founded in 1998 and is headquartered in San Diego, California.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.